Evidence map›Paper›PMID 30705500›Full record

ArticleClinical diabetes : a publication of the American Diabetes Association2019

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.

Louis Chaykin, Anuj Bhargava, Raymond de la Rosa, Carol H Wysham, Lone Nørgård Troelsen, Signe H Østoft, Athena Philis-Tsimikas

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical diabetes : a publication of the American Diabetes Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02030600 (A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02030600 phase3completednot on this map

A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)

TypeinterventionalSponsorNovo Nordisk A/SRan2014 to 2015Enrolled721ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec, insulin glargine
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Louis ChaykinMeridien Research, Bradenton, FL.
Anuj BhargavaIowa Diabetes and Endocrinology Research Center, Des Moines, IA.
Raymond de la RosaPaducah Endocrinology, Paducah, KY.
Carol H WyshamRockwood Clinic, University of Washington, Spokane, WA.
Lone Nørgård TroelsenNovo Nordisk A/S, Søborg, Denmark.
Signe H ØstoftNovo Nordisk A/S, Søborg, Denmark.
Athena Philis-TsimikasScripps Whittier Diabetes Institute, San Diego, CA.
Novo Nordisk (Denmark) · DKIowa Diabetes and Endocrinology Research Center · USMeridien Research · USPain Management Center of Paducah · USScripps Whittier Diabetes Institute · USUniversity of Washington · US

Funding

New York Regional Center for Diabetes Translation Research - Translational Intervention Methodology CoreP30DK111022 · NIDDK · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JEFFREY GONZALEZ · 2016 to 2026
$7.8M
NIDDK NIH HHS P30 DK111022
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30705500
PMCPMC6336128
OpenAlexW2892632004

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.